{
    "nctId": "NCT04936295",
    "briefTitle": "Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation",
    "officialTitle": "A Phase II Study of the Efficacy and Tolerability of Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer Patients With FGFR Mutation",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 61,
    "primaryOutcomeMeasure": "Clinical benefit rate (CBR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form;\n2. 18-75 years old;\n3. Women in any menstrual state, premenopausal or perimenopausal patients need to receive luteinizing hormone releasing hormone(LHRH) analogue;\n4. Eastern Cooperative Oncology Group (ECOG) score \\[0-1\\] points;\n5. The expected survival period is \u226512 weeks;\n6. The diagnosis of invasive carcinoma by histology or cytology; Estrogen receptor (ER) positive (defined as \\>1% nuclear ER staining); HER2 negative (defined as IHC 0 or 1+, or HER2(2+) with HER2 FISH detection no amplification);\n7. Inoperable or recurrent/metastatic breast cancer patients with aromatase inhibitor treatment failure;\n8. In the state of disease progression before enrollment;\n9. There are FGFR mutations, which meets any of the following: \u2460Immunohistochemical method: any subtype of FGFR1/2/3/4 is positive; \u2461 Gene detection results of tissue/blood sample shows that any subtype of FGFR1/2/3/4 has functional variation such as amplification, activating mutation or fusion;\n10. Measurable disease according to RECIST version 1.1 or only bone metastasis;\n11. Adequate hematological, hepatic function;\n12. Doppler ultrasound: left ventricular ejection fraction (LVEF) \u226550%.\n\nExclusion Criteria:\n\n1. Have used Fulvestrant or its analogues;\n2. History of other primary malignancy;\n3. Allergic to the ingredients of Anlotinib Hydrochloride Capsules;\n4. Previously received targeted drug therapy for FGFR;\n5. Received chemotherapy within 4 weeks before enrollment;\n6. Received endocrine therapy within 2 weeks before enrollment;\n7. Patients with currently symptomatic brain or meningeal metastasis;\n8. Concomitant diseases/conditions that is not controllable, and any other major illness that, in the investigator's judgment, will substantially increase the risk associated with the patient's participation in this study;\n9. Patients who cannot accept drugs orally;\n10. Any other situation that the investigator judges cannot be enrolled in the study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}